Dr. Johnson on the Limitations of Biomarkers in Melanoma
Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.
Related Articles
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.
Functional Precision Medicine Method Aids Treatment Decision-Making in R/R Pediatric Cancers
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent…
Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.